Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
1.260
+0.040 (3.28%)
At close: Apr 1, 2025, 4:00 PM
1.286
+0.026 (2.07%)
After-hours: Apr 1, 2025, 5:04 PM EDT
Galectin Therapeutics Market Cap
Galectin Therapeutics has a market cap or net worth of $79.61 million as of April 1, 2025. Its market cap has decreased by -35.01% in one year.
Market Cap
79.61M
Enterprise Value
154.61M
1-Year Change
-35.01%
Ranking
Category
Stock Price
$1.26
Market Cap Chart
Since September 9, 2002, Galectin Therapeutics's market cap has increased from $31.60M to $79.61M, an increase of 151.92%. That is a compound annual growth rate of 4.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 31, 2025 | 77.10M | -4.81% |
| Dec 31, 2024 | 81.00M | -21.13% |
| Dec 29, 2023 | 102.70M | 52.83% |
| Dec 30, 2022 | 67.20M | -45.28% |
| Dec 31, 2021 | 122.80M | -3.99% |
| Dec 31, 2020 | 127.90M | -21.39% |
| Dec 31, 2019 | 162.70M | 15.31% |
| Dec 31, 2018 | 141.10M | 18.57% |
| Dec 29, 2017 | 119.00M | 313.19% |
| Dec 30, 2016 | 28.80M | -26.53% |
| Dec 31, 2015 | 39.20M | -48.96% |
| Dec 31, 2014 | 76.80M | -48.11% |
| Dec 31, 2013 | 148.00M | 352.60% |
| Dec 31, 2012 | 32.70M | -55.81% |
| Dec 30, 2011 | 74.00M | 32.14% |
| Dec 31, 2010 | 56.00M | 288.89% |
| Dec 31, 2009 | 14.40M | 234.88% |
| Dec 31, 2008 | 4.30M | -84.81% |
| Dec 31, 2007 | 28.30M | 111.19% |
| Dec 29, 2006 | 13.40M | -83.91% |
| Dec 30, 2005 | 83.30M | 21.96% |
| Dec 31, 2004 | 68.30M | -23.94% |
| Dec 31, 2003 | 89.80M | 72.69% |
| Dec 31, 2002 | 52.00M | 64.56% |
View and export this data all the way back to 2002.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 731.26B |
| UnitedHealth Group | 478.21B |
| Johnson & Johnson | 398.95B |
| AbbVie | 367.19B |
| Novo Nordisk | 305.46B |
| Abbott Laboratories | 228.79B |
| AstraZeneca | 225.46B |
| Merck & Co. | 224.84B |